The invention relates to the novel base-substituted benzylamine analogs of general formula (I), wherein A represents P2-P1 with P1═(A) and P2═(B), for use as coagulation factor Xa inhibitors. The invention also relates to the production and use of said analogs in the therapy and prophylaxis of cardiovascular diseases and thromboembolic events.